Altris AI introduced its Advanced Optic Disc (OD) Analysis, building on its earlier innovation with Ganglion Cell Complex (GCC) Asymmetry Analysis to enhance the improvements from the Altris AI macula module, the company said in a press release.
The AI-powered Advanced Optic Disc Analysis module evaluates optic disc parameters using optical coherence tomography (OCT), providing personalized assessments by accounting for individual disc sizes and angle of rim absence. This tailored approach, the company said, eliminates reliance on normative databases, making evaluations more accurate and patient-specific.
Altris AI’s platform assigns a severity score for optic disc damage on a scale from 1 to 10, offering valuable insights into glaucomatous changes, the company said. Furthermore, it enables cross-evaluation across different OCT systems, allowing practitioners to analyze both macula and optic disc pathology, even when data originates from multiple OCT devices.
The key parameters of the Optic Disc Analysis for glaucoma include:
- Disc area
- Cup area
- Cup volume
- Minimal Cup depth
- Maximum Cup depth
- Cup/Disc area ratio
- Rim Absence angle
- Disc-Damage Likelihood Scale (DDLS)
The Altris AI glaucoma module is compatible with various OCT scan protocols, including:
- 3D OCT optic disc scans
- 3D OCT horizontal-wide scans
- 3D OCT vertical-wide scans
- OCT optic disc raster scans
According to the company, combining GCC Asymmetry and Advanced Optic Disc analysis for glaucoma empower enabling eyecare practitioners (ECPs) to make faster evaluations and explore a wider range of treatment options. It also provides ECPs with timely, actionable data, ultimately improving patient outcomes and care, the company said.
“The launch of our Advanced Optic Disc Analysis module marks a pivotal step forward in glaucoma care," said Maria Znamenska, MD, PhD, chief medical officer at Altris AI, in the press release. "By combining the gold standard of optic disc evaluation with AI-powered precision, we’re equipping eyecare professionals with the tools to make more accurate and timely diagnosis of this vision-threatening disorder. This innovation not only reduces false positive referrals but also enhances early detection and treatment planning—ensuring better outcomes for patients and optimizing health care resources. Together with GCC asymmetry analysis, our platform empowers clinicians to elevate the standard of glaucoma care, offering hope to millions at risk of vision loss.”